Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RLFTF DD (copy) by OU2 on Ya-h00 Email received from Relief Investor Relations in response to an email I sent regarding the RS projections shared this past week.
It is clear from their response they were projecting midterm to long-term and not the immediate short-term (prior to top line results). In the direct quote below they used the term “future” as in not now. Here is the exact quote
“A reverse stock split on the Swiss stock exchange is certainly an option Relief may explore in the future or the issuance of an American depositary receipt (ADR). These steps would be taken in order to enable the Company to have a more attractive stock price per share. Relief will continue to evaluate this process in 2021 and update shareholders should more definitive plans take shape.”
So everyone needs to calm down. There are no definitive plans - meaning nothing immediate.
Furthermore, the language suggests they would not do anything now prior to RCT data reveal, and possibly not even until after EUA.
It appears that the 1/20 conversion was likely an illustration of what they can do to uplist, albeit the choice of timing and disclosing an exact ratio caused undo concern with investors.
RS is very likely but not until strength is established for the company.
There are multiple catalysts to tie a favorable RS to, such as EUA for IV formula, or Top Line for Inhaled formula, or full BLA for either.
To do it prior adds unnecessary stress on the share price, but a favorable RS with wind in our sails is an amazing opportunity that we should all support if you understand corporate finance.
Long RLFTF,
OU
Blockchain Provides Legal High for Cannabis Users https://beincrypto.com/?p=95692 via https://beincrypto.com/blockchain-provides-legal-high-for-cannabis-users/
Could Blockchain Be the Next Game-Changing Technology for the Cannabis Industry? - Cannabis Business Times http://www.cannabisbusinesstimes.com/article/is-cannabis-ready-for-blockchain-testing-tracing/#.X_yX4Xe7RCo.twitter
$RLFTF (related) About HHS, ASPR, and BARDA:
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services.
The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures (MCMs) – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats.
To date, BARDA-supported MCMs have achieved 56 FDA approvals, licensures or clearances.
For more on BARDA’s portfolio for COVID-19 diagnostics, vaccines and treatments and about partnering with BARDA, visit medicalcountermeasures.gov.
To learn more about federal support for the all-of-America COVID-19 response, visit coronavirus.gov.
https://www.quantumleaphealth.org/media/hhs-dod-engage-quantum-leap-healthcare-collaborative-in-search-for-effective-treatments-for-the-sickest-covid-19-patients?fbclid=IwAR0_i1hu7WpVPCwyEZmrMyOjQ0nqqzBpcUcOFKuZVPPMddbVwYUoWtSkwLY
mHH? Done : "For now, the fate of the American stoner rests on Georgia voters.
Opinion post by a Texan TXB on another board w/a Company possibly looking to get into CBD/MJ market:
Cannabis industry is about to explode in the US. We’ll most likely see legalization (or at least decriminalization) on the federal level in the next year or two.
States are continuing to legalize. Even here in Texas, it’s been on the docket for legalization for a few years now and is even part of the Texas Republican Party platform.
It’s going to happen soon here, and then all other Red states will follow suit. Lots of money to be made with any company getting into the fold now
Unbelievable
$APYP 4sure !!!
$RLFTF..it could also add to FOMO.. I had a post on another board and tw--ter the other day on the % splits mostly in favor of Relief and it was the top post a good part of the day.. w/approval I'm sure the doors will be rushed..
..only been here a short time.. and it's already bewildering!!!
;) ..lots of share-loaded diapers around here.. there will be noise..
$APYP CBD-Marijuana industry is building steam... depending on the new company moves.. this could go way beyond current expectation.
$RLFTF #Zyesami - Aviptadil RLF-100
No.. it was standard fee there.. just p/u another 5,000 and paid another $50.oo on my other acc. I won't care when it's $6.oo+ ;)
..yeah, not sure either.. but the AI industry $$#'s look good going forward.. ;)
Marijuana: Why the drug became illegal and the future of legalization http://a.msn.com/09/en-us/BB1cv9Kl?ocid=st
?? could it be ??
POET Technologies Enters Artificial Intelligence Market with Technology Leader in Photonic Computing
TORONTO, Ontario, January 6, 2021 – POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today announced that it has entered into development and supply agreements with a technology leader in photonic neural network systems for Artificial Intelligence (AI) applications.
Artificial Intelligence, at the cusp of its own revolutionary impact to humanity, is driving an unprecedented demand for computation at the same time that the physics of digital semiconductors, driven by Moore’s law, is reaching its end. Transistor scaling is approaching its limits and AI accelerator companies are struggling to keep pace with demands, particularly in “edge” applications that require greater power and cost efficiency. Domain-specific architectures targeted to AI workloads can make up for some of the slowdown in transistor advances but that approach also has its limits.
The chipset market for AI applications is projected to grow from approximately $18 billion in 2020 to over $65 billion by 2025. POET’s new development and supply agreement for photonic AI computing represents an entry point into this new large and extremely high-growth market. POET’s customer for these applications is breaking the digital semiconductor mold by integrating photonics into accelerators for AI workloads, thereby enabling step-change advancements in AI computation. Harnessing light to perform data-parallel calculations is many orders-of-magnitude faster, more power efficient, and lower cost than in traditional semiconductors. Photonic computing changes the game in the field of Artificial Intelligence.
“Photonics has been readied for optical computing as a result of over a decade of advancements in photonics design and fabrication driven by telecommunications and data communication and promises to be the technology to usher in the next era of rapid growth for AI computing,” commented Suresh Venkatesan, the Company’s Chairman & CEO. “POET is now well positioned to participate meaningfully for a new class of high-volume, high-growth applications, expanding the addressable markets for our Optical Engines and Optical Interposer platform products. In addition to highlighting the tremendous adaptability of the POET Optical Interposer platform, this project is anticipated to result in revenue for POET this year in the form of NRE and potentially initial product sales.”
“Beyond The Press Release”
POET Technologies goes “Beyond The Press Release” to discuss today’s news. Shareholders and other interested parties are encouraged to check back on this link before market open on the morning of Thursday, January 7, 2021.
https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/752378-poet-technologies-goes-beyond-the-press-release/messages/2296149#message
Vinergy Cannabis Cap (VNNYF) 0.0366 ? 0.0 (0.00%) https://investorshub.advfn.com/Vinergy-Cannabis-Capital-Inc-VNNYF-31763/
$RLFTF JJ interview - 04.01.2021 (PART 1)
NeuroRx CEO, Jonathan Javitt, and Head of Operations/CCO, Robert Besthof, discuss the logistics and trial progress of their COVID-19 drug.
Operating clinical trials of a COVID-19 drug comes with many challenges, not the least of the pandemic's limitations. NeuroRx CEO Jonathan Javitt, MD, MPH, and Head of Operations/CCO Robert Besthof discuss the logistics and clinical trial progress of their COVID-19 drug, aviptadil.
Moe Alsumidaie: What challenges have you experienced in your studies during the COVID-19 pandemic?
Jonathan Javitt: Probably the most significant challenge has been keeping our people at our study sites healthy. We had three study sites pause or slow down because staff members on the front lines got COVID-19, and some of them needed to be hospitalized. We had sites go down because hospitals were so overwhelmed that they needed to pull every competent person off research.
Keeping a study going in the middle of an epidemic is the opposite of what you would expect. People say, "Oh, there are a million cases. Enrollment ought to be easy." Yes, there are a million cases, but it is like trying to drink water from a fire hose.
MA: When those sites faced challenges, what did you do? Did enrollment stop?
JJ: Once a patient has been treated in our study, the endpoints—survival, recovery from respiratory failure, and whether the patient is on a ventilator or not—are collected automatically. However, enrolling people, getting the infusions done, and obtaining informed consent depends on highly trained people. If you lose them, you pause recruitment at that site until they recover.
MA: Have you adapted your protocol at all?
JJ: When we started the study, 70% of people who developed COVID-19 respiratory failure died of it, so survival was our primary endpoint. However, over the first three months of the pandemic, medical care got much more effective. Suddenly, everybody was getting anticoagulants and steroids. Ventilator use decreased, and survival rates doubled.
Our protocol was initially for COVID-19 associated acute respiratory distress syndrome, and then the Food and Drug Administration (FDA) released updated nomenclature that now everybody uses: COVID-19 with respiratory failure. That is critical because aviptadil targets the cells in the lung that make surfactant, which the lung needs to oxygenate the blood and the rest of the body. The new FDA nomenclature was ideal for our study. We were always targeting respiratory failure.
MA: What steps is NeuroRx taking to maximize operational efficiency in these clinical studies? What have you done to ensure enrollment and recruitment?
JJ: The most crucial difference between the average pharma company and us is that we are doing the clinical operations ourselves. We used a Contract Research Organization (CRO) for the electronic data capture backbone, but we are running all the trial aspects. The study coordinators know they are not talking to some executive who is doing their study today and another study tomorrow; they are talking to us directly.
The thing probably driving enrollment more than anything is that the study staff see patients getting better. We have published X-rays with patients with this white COVID-19 lung clearing in 48 to 96 hours. The study staff has not seen that before with COVID. There is nothing health professionals want more than to see their patients get better.
Robert Besthof: Our team is in close and continuous contact with the sites.
When a site reaches out to us for something urgent, we respond, no matter if it is at night or on the weekends. COVID-19 does not pause, and neither do we.
This is one element that distinguishes NeuroRx and has enabled us to progress this study so rapidly. If there are medical questions, we allow a rapid dialogue with a pulmonologist / critical care physician or a cardiologist / critical care physician, who support us in this study as consultants.
This vital communication with the sites also helps us prepare for potential challenges, such as the recent surge of hospital admissions that required rapid provisioning of additional drug supplies or maintaining communication continuity when some employees went on furlough.
We are very proud of having this level of trust and communication with our sites. Despite all the technology in this pandemic, the human element is critical.
SECOND PART:
MA: How did you determine site feasibility for the study?
JJ: We had to have sites where the Intensive Care Unit (ICU) had critical care pulmonology facilities. We were looking for professionals who were double boarded in critical care and pulmonology. We wanted to be evaluating the functionality of our drug with the best possible care.
We also looked for people who have academic credibility with research experience and NIH grants. But first and foremost, we looked for outstanding clinicians with great clinical research teams, especially the coordinators; the kind of person you would want taking care of you if, God forbid, you were in an ICU with COVID.
MA: What about choosing the location of the sites?
JJ: We learned early on. For instance, we announced that NYU Langone would be one of our lead sites. By the time we had the study set up, the epidemic had crested in New York, and new admissions had plummeted. So, we spent much time looking at the maps and understanding where the pandemic was headed next.
MA: Have there been any challenges with drug delivery?
RB: Drug delivery is subject to the challenges of our times. Fortunately, due to our team's close contact with the clinical sites, we can closely track the delivery of aviptadil to the sites.
The most unfortunate circumstances occur when final approval for the participation of a site and its first patient in our Expanded Access Program (EAP) is received on a Friday afternoon, and due to the remoteness of a site, shipping services are not able to deliver the drug until Monday. This affects rural areas more, but we aim to help no matter where you are.
MA: Could you tell me about your EAP? What kind of patients can access it?
JJ: We have treated about 150 patients in the EAP. These are patients that have comorbidities that would exclude them from the randomized control trial. If these patients get to the point where they have developed respiratory failure from COVID-19, they have an 80% mortality rate. In our EAP, we have about 75% survival.
We have people whose families worry that their loved one is terminal, and the patient goes home on room air. It is very striking.
MA: Because of your hands-on approach, you must be interacting with patients directly.
JJ: We have become part of families in some ways. We had two sons, both physicians, drive from Arizona to Los Angeles to get the study drug for their father. The families that have been able to get their relatives into the EAP have gone to great lengths to do it.
RB: Having lost family friends to COVID-19, we approach patients with great empathy. Most individuals call looking for any opportunity to treat a loved one who has been in a critical stage for several weeks. The hospital has told them that they had exhausted all options, typically because they are in remote locations and not participating in clinical studies.
We direct them to information on our website for a treating physician to apply to our EAP. We have to clarify that aviptadil is in clinical studies and that the physician must make the decision. Unfortunately, for some hospitals, the process can take several days and frequently more than one week, and the condition of the patient can continue to deteriorate.
JJ: It is undoubtedly, the most challenging clinical trial I have ever been involved in, but by far the most rewarding.
Moe Alsumidaie, MBA, MSF, is a thought leader and expert in the application of business analytics toward clinical trials, and Editorial Advisory Board member for and regular contributor to Applied Clinical Trials.
Maybe a R/M soon..
$HTDS Good find.. Thanks
$RLFTF Interesting opinion post (copy) by Joshua on ya-hoo 2 hours ago
I would be lying if I didn’t say I’ve been a bit frustrated with the company. For many here it seems like the company has been withholding information from shareholders. It seems to have had a negative effect on the SP, which is why we have been irritated when some of that news has been revealed to us.
But if we look deeper we can see that the company is not simply withholding bad news, they are also withholding the good stuff. Look no further then NeuroRX’s presentation to Big Rock. Specifically I would like to point to slides #17 and 18. The highlights
-Inhaled Aviptadil trial initiated with Covance in December.
-Contract signed to supply drug to I-Spy
clinical trial platform led by Quantam Leap Healthcare Collaborative
-Inclusion in NIH TESICO/Activ3b trial
This information is extremely positive stuff, but was never shared via PR by Relief. Why? Well...
NeuroRX and Relief are separate companies, so it makes disclosing information to shareholders quite interesting. These moves/transactions listed on slides 17 and 18 are the work of NeuroRX, not Relief. But the reality is they have a similar goal. They both want Aviptadil to be granted EUA and full approval so that it can help people and make the companies money. The fate of both companies are very much tied to Aviptadil. NeuroRX expanding to a publicly traded company has made that move with Aviptadil as a very important part of that transaction (see slide #4).
And so we complain about getting bad PR, or lack of PR, but the company is obviously not sharing all the information with us. It seems there are lots of good things going on in the background and since much of that is happening in the US (NeuroRX’s territory and not necessarily Reliefs) we have been left in the dark. But if we look deeper and examine the info we can find the bread crumbs.
NeuroRX didn’t lie in their investor presentation to Big Rock. Lots of good stuff happening we don’t even know about and believe me NeuroRX is very much invested in the success of Aviptadil. They are working very hard to get this to market and I trust Javitt and the gang will get it there. GLTA
$RLFTF A little #Zyesami - Aviptadil RLF-100 maybe?? -- He Was Hospitalized for Covid-19. Then Hospitalized Again. And Again. http://a.msn.com/01/en-us/BB1ckYGD?ocid=st
Post clips from around the web..
FLASKWORKS' owned by NWBO, its individualized treatment production device, MIcroDen, has already been manufactured by CORNING and is currently being marketed to pharmas producing similar treatments requiring sterilized environments for culture/medication production. FLASKWORKS and Corning would not have had MicroDen bought from them by NWBO with stock options without having done their own analysis of the NWBO's profitability.
NWBO is ready to hit the ground running.
If the results were bad news, we would have heard by now. My bet is the final data is a go and NWBO is in the process of writing the article detailing scientifically its success and arranging for publication of positive results in a major medical journal. That takes time to fit into publication schedules. A treatment break thru of this magnitude is not simply publicized in a pedestrian press release. Maybe no. Maybe yes. I say yes!
Good news is coming!
----------
Here is an extract from
Herald-Tribune today's article:
"However, and this is a huge however, if the trial had failed, SEC rules require that they had to reveal that to investors within four days.
Instead, weeks have passed without a word, so by inference we now know the trial was a success. This is the largest and longest such trial ever run and the only one of more than 400 to reach a happy result.
The lead investigators and their collaborators are hard at work on a paper to be published in a major medical journal. Until then, the company is in a “quiet period.”"
-------------
I wish that we could really infer that the trial is a success. Fact is, the FDA makes that decision. They can't decide until they have an application and all of the supporting data. The odds of approval are higher now for sure, but currently there is no telling whether the FDA will move to make a label so NWBO can market/help people; or demand a PIV; or what... all I'm sayin' is that there will be a time to make yourself fat or get yourself slaughtered.
---------
Its getting clearer with each passing day that the TLD will be favorable! Action today may be leakage of data about to be released!!
--------
At this time very little downside risk. If this failed we would have known by now based on SEC 4 day rule. Remember, the FDA mandated cross over option in this trial so there is absolutely no way the would fail this study based on that fact. Agree, it may be more difficult to analyze but I am certain the statistics will be correctly identified. My money is on approval by the UK, Germany and Canada. LP knew that the FDA is a puppet for lobbyists so she was brilliant in her decision to develop the trial in 4 countries! Merry Christmas longs
..wasn't trying to say anything really.. put the question marks there for a reason and knew it was a parody account.. it's just that LWLG is hardly ever mentioned on twitter and even if it's a joke it's still exposure and people will talk.. a few of the responses to my post were unnecessary I don't know why people here can't just relax and try to be more friendly.. but it's always been that way around here anyways.. o'well maybe we should have a few Celebrity shareholder boxing matches at the next annual meeting.
$APYP A Beefy Skunk ... Let's make some NOISE !!!
..maybe the old data doesn't matter w/the new coming in.. ;)
naH He's alright.. just posts charts while getting attention to his trading programs.. lots of myth around his posts.. ;)
$APYP OTC Info
https://www.otcmarkets.com/stock/APYP/overview
..it could be that other large holders want to take in millions of shares rally cheap and the run it later on into dollars when rec. Marijuana is legal.. I don't mind the gamble.. screw it.
$APYP Pink current
$APYP Pink current
$RLFTF Robinhood, SPAC playes..etc, I glanced something like 70 down to 40? .. not sure.. but I believe people are becoming aware of the essential ingredient RLF-100 owned by $RLFTF
I'm guessing the best way to make noise is go to you local news station and let your request have a life and reach of it's own.. hope everything works out for you and your family.
OnBoard Polymer Buttons patented by me .. .10 cents a push .. I make twice the bottle return collector guy down the street ;) gonna buy me some more shares with the funds !!
$MSTO MasterBeat Corporation Announces Malone Bailey, LLP has Completed its 2018 and 2019 Audit of the Company
https://www.otcmarkets.com/stock/MSTO/news/MasterBeat-Corporation-Announces-Malone-Bailey-LLP-has-Completed-its-2018-and-2019-Audit-of-the-Company?id=284136
..would'a been nice for the hurdles to have been brought low so many could've been treated in the previous.. so sad.
$RLFTF With all that's going on more shares, Companies.. Heavy hitters joining.. etc.. I'm starting to think they're setting up this little company to Be, Act, Handle and Produce Like a Big Pharma.
----------
Look at pg 4: “Validation from NIH, BARDA, and other stakeholders"”
https://www.sec.gov/Archives/edgar/data/1719406/000165495420013699/brpa_ex992.htm - DD by vader69
-----
DD by JB (copy) Some thoughts on the SEC Filing:
https://www.sec.gov/Archives/edgar/data/1719406/000165495420013699/brpa_ex992.htm
The NRX SPAC merger document has provided our most recent up to date look at Relief’s data to date, specifically with the trial and future events. This SEC document was just filed yesterday. It notes that we now have: 200 enrolled in the clinical trial and 235
enrolled in the EAP trial.
This is a big gain from the 12/7/20 PR where they announced the 165 milestone in the clinical trial and 200 in the EAP.
More importantly, the SEC document mentions on page 4 “Validation from NIH, BARDA, and other stakeholders"
Lastly, on pg 18 of the report, “Inclusion in NIH TESICO/ACTIV3b trial” and an I-spy clinical trial contract for quantum healthcare.
ACTIV stands for Accelerating COVID-19 Therapeutic Interventions and Vaccines.
Heres the US NIH's ACTIV website:
https://www.nih.gov/research-training/medical-research-initiatives/activ#overview
Here is info about the I-Spy trial
https://www.quantumleaphealth.org/portfolio/i-spy-covid
BARDA as a possible stake holder on page 4 is a big deal. The RLF EGM PR specifically said "not directly" for a reason. I feel like we’re finally getting more proof of all the great things RLF & NeuroRx have been doing these past few months while we held. I suspect when we finally get EUA, there’s going to be a flood of news regarding Data,OWS, BARDA, manufacturing with Bachum, Nephron -and delivery with our unknown delivery contractor
Bottom line is that "ITS A BIG FKN DEAL"...
Best,
-JB